Cargando…

A tool to help patients visualize ASCVD risk and the potential impact of risk-lowering interventions

Risk assessment is a fundamental step in the current approach to primary prevention of atherosclerotic cardiovascular disease (ASCVD). When considering pharmacotherapy for primary prevention of ASCVD, current prevention guidelines in the United States recommend the use of the pooled cohort equations...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mendez, Keegan, Rane, Manas, Orkaby, Ariela R., Gaziano, J. Michael
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2022
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9789346/ https://www.ncbi.nlm.nih.gov/pubmed/36573190 http://dx.doi.org/10.1016/j.ijcrp.2022.200159

Ejemplares similares

Predictive value of ASCVD risk score for mortality and major adverse cardiovascular events in the year following a COVID-19 infection among US Veterans()
por: Guardino, Eric T., et al.
Publicado: (2023)

The Potential Role of Biomarkers Associated with ASCVD Risk: Risk-Enhancing Biomarkers
por: Choi, Seonghoon
Publicado: (2019)

Newer and Emerging LDL-C Lowering Agents and Implications for ASCVD Residual Risk
por: Rikhi, Rishi, et al.
Publicado: (2022)

Gauging ASCVD Risk, Does Race Matter?
por: Zuo, Ming-Liang, et al.
Publicado: (2022)

Association of hyperuricemia combined with sarcopenia on ASCVD risk
por: Nie, Guqiao, et al.
Publicado: (2023)

IMPACT OF THE COVID-19 PANDEMIC ON THE MANAGEMENT OF RISK FACTORS IN PATIENTS WITH ASCVD
por: Karalis, Dean, et al.
Publicado: (2023)

Maximizing the Mini-Cog: Cognitive Decline Caused by Carotid Artery Stenosis
por: Streiter, Shoshana, et al.
Publicado: (2020)

Identifying Opportunities for Impact of Community-Based Pharmacist-Led Biometric Health Screenings on ASCVD Risk
por: Newell, Bradley J., et al.
Publicado: (2023)

Combination of Endoglin and ASCVD Risk Assessment Improves Carotid Subclinical Atherosclerosis Recognition
por: Li, Qiaowei, et al.
Publicado: (2020)

RELATION OF 10-YEAR ASCVD RISK SCORE WITH SEVERE COVID-19 OUTCOMES
por: Arif, Yousif, et al.
Publicado: (2022)

Comparison of Framingham Cardiovascular Risk Criteria and ASCVD Score in Iranian Obese Patients
por: Hasani-Ranjbar, Shirin, et al.
Publicado: (2023)

Metabolomics profile and 10-year atherosclerotic cardiovascular disease (ASCVD) risk score
por: Dehghanbanadaki, Hojat, et al.
Publicado: (2023)

Highlights in ASCVD Primary Prevention for 2021
por: Polonsky, Tamar S., et al.
Publicado: (2022)

COVID-19 associated risks of myocardial infarction in persons with familial hypercholesterolemia with or without ASCVD
por: Myers, Kelly D., et al.
Publicado: (2021)

External validation of the ACC/AHA ASCVD risk score in a Colombian population cohort
por: Rodríguez-Ariza, Carlos Daniel, et al.
Publicado: (2023)

Health Literacy is Essential to ASCVD Prevention in Youth
por: Mann, Harnoor K., et al.
Publicado: (2023)

10-year ASCVD risk is positively correlated with depressive symptoms in a large general population
por: Sun, Guo-Zhe, et al.
Publicado: (2019)

Taking prevention to the next step: implementation of a brief, sustainable frailty assessment in a cardiology clinic
por: Orkaby, Ariela R, et al.
Publicado: (2021)

Cost effectiveness of interventions to improve adherence to statin therapy in ASCVD patients in the United States
por: Armstrong, Shannon O, et al.
Publicado: (2019)

Effects of weight change on apolipoprotein B-containing emerging atherosclerotic cardiovascular disease (ASCVD) risk factors
por: Dansinger, Michael L., et al.
Publicado: (2019)

Ten-year risk assessment for cardiovascular diseases using ASCVD risk estimator plus: outcomes from hypertension and diabetes patients
por: Osoro, Ian, et al.
Publicado: (2023)

Utility of coronary artery calcium in refining 10-year ASCVD risk prediction using a Thai CV risk score
por: Tiansuwan, Noppanat, et al.
Publicado: (2023)

Chinese ASCVD risk equations rather than pooled cohort equations are better to identify macro- and microcirculation abnormalities
por: Li, Qiaowei, et al.
Publicado: (2020)

MBOAT7 rs641738 (C>T) is associated with NAFLD progression in men and decreased ASCVD risk in elder Chinese population
por: Xu, Xiaoyi, et al.
Publicado: (2023)

Expanding statin use for prevention of ASCVD in Indians: Reasoned and simplified proposals
por: Enas, Enas A., et al.
Publicado: (2020)

Healthcare Resource Utilization, Cardiovascular Event Rate and Use of Lipid-Lowering Therapies in Secondary Prevention of ASCVD in Hospitalized Patients in Italy
por: Sciattella, Paolo, et al.
Publicado: (2021)

SCREENING OF US VETERANS AT HIGH RISK FOR OUTCOMES FOLLOWING COVID-19 BY FRAILTY STATUS
por: Park, Catherine, et al.
Publicado: (2022)

979. BMI and ASCVD Risk Score Changes in Virologically Suppressed Patients with HIV Switching from TDF to TAF Containing ART
por: Schafer, Jason J, et al.
Publicado: (2019)

615. Overlooking those at Intermediate Risk? ASCVD Prevention Measures among People Living with HIV at an Urban Academic Medical Center
por: Liotta, Mark, et al.
Publicado: (2020)

Sex-specific performance of the ASCVD pooled cohort equation risk calculator as a correlate of coronary artery calcium in Kampala, Uganda
por: Kentoffio, Katherine, et al.
Publicado: (2022)

A Review of Progress on Targeting LDL Receptor-Dependent and -Independent Pathways for the Treatment of Hypercholesterolemia, a Major Risk Factor of ASCVD
por: Srivastava, Rai Ajit K.
Publicado: (2023)

Inverse Association between Educational Status and Coronary CT Calcium Scores: Should We Reflect This in Our ASCVD Risk Assumptions?
por: Dienhart, Christiane, et al.
Publicado: (2023)

Feasibility of Frailty Assessment Integrated with Cardiac Implantable Electronic Device Clinic Follow-up: A Pilot Investigation
por: Albakri, Abdel, et al.
Publicado: (2021)

The risk matrix approach: a helpful tool weighing probability and impact when deciding on preventive and diagnostic interventions
por: Lemmens, Stéphanie M. P., et al.
Publicado: (2022)

Apolipoprotein E polymorphisms contribute to statin response in Chinese ASCVD patients with dyslipidemia
por: Zhang, Lei, et al.
Publicado: (2019)

Analisi di costo-utilità di evolocumab in pazienti con ASCVD in Italia
por: Marcellusi, Andrea, et al.
Publicado: (2021)

ASCVD risk stratification modifies the effect of HbA1c on cardiovascular events among patients with type 2 diabetes mellitus with basic to moderate risk
por: Zhang, Hongmei, et al.
Publicado: (2020)

The Effects of Intensive Blood Pressure Control on Cardiovascular Outcomes Based on 10-Year ASCVD Risk Score: An Analysis of a Clinical Trial
por: Alborzi, Alireza, et al.
Publicado: (2021)

Effect of different antidiabetic medications on atherosclerotic cardiovascular disease (ASCVD) risk score among patients with type-2 diabetes mellitus: A multicenter non-interventional observational study
por: Gillani, Syed Wasif, et al.
Publicado: (2022)

Parâmetros Ecocardiográficos Simples podem Substituir o Cálculo do Modelo Probabilístico ASCVD?
por: Silva, Tonnison de Oliveira, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_dequbh93u2i4kro1hk930hj4af